Get More Information on Healthcare Market - Request Sample Report
The Healthcare Market Size was valued at USD 21,222.5 Billion in 2023, and is expected to reach USD 44,760.73 Billion by 2032, and grow at a CAGR of 9.07% over the forecast period 2024-2032.
Government policies and funding are central to the growth of the healthcare industry as it operates alongside strict government regulations. The World Health Organization (WHO) measured global healthcare expenditure as growing year-over-year and reaching an estimated USD 8.3 Trillion in 2020. With countries all over the world spending more money than ever on their healthcare systems, that is a strong indication of just how vital it feels to so many governments are keep and enhance what they offer in this regard. According to the Centers for Medicare & Medicaid Services (and not accounting for $1.9 trillion spending in the coronavirus relief package signed by President Joe Biden), healthcare expenditures had been set at 19.7% of U.S GDP. It is such a large amount which in turn reflects on how the country has taken into account that people should always be able to consult for quality services, adding some of them were unaffordable and the majority had forced families to go bankrupt. Much of this spending is spurred by government-led efforts to increase access and quality in the healthcare sector.
For example, The Affordable Care Act (ACA) has been instrumental in boosting the number of people with insurance making healthcare services readily available to all, and promoting market expansion. Equally, the European Union has invested heavily in healthcare infrastructure as clear evidence of its commitment to protect the health and safety of all people living there. For example, Germany, and France are the ones who spend a lot and give on improving facilities to make healthcare world-class. It is backed by strong investments and is underpinned by comprehensive universal healthcare schemes that ensure access to necessary medical services for all citizens thus providing a very inclusive as well as holistic healthcare platform. This has revolutionized healthcare services and is also epitomized by the universal healthcare programs in place throughout most of Europe. These schemes have been conceptualized to bring health access on an equitable basis for all, keeping those in need - across financial and social strata; at the center. This way, it promotes the health of everybody and therefore causes an increase in market intervention for providing services (and products) at times as well.
Moreover, government investments are essential for funding the healthcare sector's research and development (R&D) operations. For example, the US government invests billions in organizations like NIH (National Institutes of Health), so they can catalyze medical research and innovation. The resulting funding encourages the growth of a healthcare market (new treatments, drugs, and medical technologies). In conjunction with national policies, international collaborations, and agreements also go a long way to shape the healthcare sector. Global health initiatives of international organizations like WHO are critical to tackling such challenges worldwide, which knows no borders and connects countries in the fight for humanity. This support and funding often come from different governments, reinforcing that global health initiatives require multiple front-line efforts. Governments everywhere have initiated steps in this direction from making healthcare facilities more accessible to tax waivers and incentives, which is an affirmation of the value it contributes both towards individual prosperity as well as communal development. Government by constantly investing in healthcare infrastructure, policies, and research ability to not only meet timely health needs but also ensure the long-term future of the healthcare sector. This strategic approach is vital for stimulating the market, encouraging innovation, and ultimately enhancing the quality of life worldwide.
KEY DRIVERS:
An Increasing Global Elderly Population Leads to a Higher Demand for Medications to Treat Chronic and Age-Related Diseases.
Continuous Advancements in Biotechnology and Pharmaceuticals Are Leading to The Development of New and More Effective Drugs.
RESTRAINTS:
The Significant Expense Involved in Research and Development Can Limit the Entry of New Companies and Restrict Innovation.
Strict Regulations and Approval Processes Can Delay the Launch of New Drugs and Increase Costs.
OPPORTUNITY:
The Growing Healthcare Infrastructure and Increasing Access to Healthcare Services in Developing Countries Offer Significant Growth Potential.
Advances In Genetic Research Are Paving the Way for Personalized Treatments Tailored to Individual Patients, Creating New Market Opportunities.
By Type
Healthcare services was the largest segment in 2023, and accounted for approximately 49.5% of the healthcare industry by type. Healthcare services are further segmented into hospitals; medical and diagnostic laboratories; physician offices; pharmacies etc.; nursing homes & residential care providers based in clinics, and hospitals (nurses, Beds). The sector has been mainly influenced by the growing incidence of chronic diseases such as diabetes, cardiovascular diseases, and cancer which demand regular medical care or long-term therapy. Another driving factor is the aging population which makes a big portion of the increase in healthcare services. The World Health Organization (WHO) projects that the world population aged 60 years and older will double by reaching nearly 2 billion in number from less than nine hundred million individuals back in 2015 as of year two thousand. This demographic change has resulted in increasing healthcare needs - from the acute care provided in hospitals to long-term nursing home care. In addition, the introduction of new methods and treatment protocols in medical treatments along with government policies to assist healthcare accessibility have contributed significantly towards development within this sector.
Need any customization research on Healthcare Market - Enquiry Now
In 2023, Geographically, North America leads the global healthcare market with 44% of the market share primarily concentrated in the United States. Thanks to the region's considerable healthcare spending, top-flight healthcare infrastructure, and large investments in research and development (R&D) it is a cut above the rest. US Healthcare Spending Hit USD 4.1 Trillion in 2020, Equaling Nearly One-Fifth of GDP Centers for Medicare & Medicaid Services (CMS) The scale of this spending reflects Swiss determination to sustain a strong healthcare system. There are a few obvious and immediate differences here; the U.S. leads in pharmaceuticals, medical devices, and biotechnology (especially in universities), for example. This underscores the government's leading role in sponsoring medical research and innovation, with a budget of roughly USD 42 billion per year declared by NIH in 2020. Another key role is overseeing the safety and effectiveness of new drugs and medical devices, which falls under consolidated authority by law to the Food & Drug Administration (FDA).
The key market players include Pfizer, Novartis, Merck & Co., Roche, Merck & Co., GSK, Sanofi, Johnson & Johnson, AstraZeneca, AbbVie, Medtronic plc & other players.
In Oct 2023, Palivizumab now has secured approval from the Central Drugs Standard Control Organization (CDSCO) for import and marketing in India by AstraZeneca Pharma Ltd.
In August 2020, Roche Pharma India opened a customer experience center in Chennai. The pharmaceutical giant states that the initiative represents a first-of-its-kind program designed to facilitate collaboration among researchers, educators, and healthcare providers to advance the future of healthcare.
Health care is one of the most important applied areas where Artificial intelligence can be implemented, medical imaging is also a part of it. The accuracy with which AI algorithms can evaluate medical pictures, including computed tomography (CT) scans, magnetic resonance imaging (MRI), and X-rays gives healthcare providers insight into their patient's condition. In many cases, it is in the best interest of patients that these technologies be used to diagnose them more rapidly and accurately. The AI can diagnose what ails someone from medical imagery that comes out of the readings given by experts. For example, AI systems may be able to assist in surgical planning by analyzing MRI data for brain tumor detection. It can also provide early diagnosis of dementia and Alzheimer's disease by studying changes in the volume and structure of the brain revealed on MRI scans. AI could also look at retinal scans to detect the early stages of diabetic retinopathy, a disorder that afflicts some people with diabetes and can lead ultimately to blindness.
Report Attributes |
Details |
Market Size in 2023 |
US$ 21,222.5 Billion |
Market Size by 2032 |
US$ 44,760.73 Billion |
CAGR |
CAGR of 9.07% From 2024 to 2032 |
Base Year |
2023 |
Forecast Period |
2024-2032 |
Historical Data |
2020-2022 |
Report Scope & Coverage |
Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
Key Segments |
By Type (Pharmaceuticals, Healthcare Services, Medical Devices, Biotechnology, Pharmacy And Retail, Home Healthcare, Diagnostics, Health And Wellness) |
Regional Analysis/Coverage |
North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
Company Profiles |
Pfizer, Novartis, Merck & Co., Roche, Merck & Co., GSK, Sanofi, Johnson & Johnson, AstraZeneca, AbbVie, Medtronic plc and other players |
Key Drivers |
•An Increasing Global Elderly Population Leads to a Higher Demand for Medications to Treat Chronic and Age-Related Diseases. |
RESTRAINTS |
•The Significant Expense Involved in Research and Development Can Limit the Entry of New Companies and Restrict Innovation. |
Ans: The U.S. led the Healthcare in the North American region with the highest revenue share in 2023.
Ans: Factors such as the Significant Expense Involved in Research and Development Can Limit the Entry of New Companies and Restrict Innovation & Strict Regulations and Approval Processes Can Delay the Launch of New Drugs and Increase Costs.
Ans The Healthcare Services held the largest share in the Healthcare Market in 2023.
AAns: The expected CAGR of the Global Healthcare Market during the forecast period is 9.07%.
Ans: The Healthcare Market was valued at USD 21,222.5 Billion in 2023.
TABLE OF CONTENTS
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Industry Flowchart
3. Research Methodology
4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
5. Porter’s 5 Forces Model
6. Pest Analysis
7. Healthcare Market Segmentation, By Type
7.1 Introduction
7.2 Pharmaceuticals
7.2.1 Production and distribution of prescription
7.2.2 Over-the-counter drug
7.2.3 Biologics
7.2.4 Others
7.3 Healthcare Services
7.3.1 Hospitals
7.3.2 Clinics
7.3.3 Nursing homes
7.3.4 Others
7.4 Medical Devices
7.4.1 MRI machines
7.4.2 Pacemakers
7.4.3 Surgical instruments
7.4.4 Diagnostic equipment
7.4.5 Others
7.5 Biotechnology
7.5.1 Development of new drugs
7.5.2 Therapies
7.5.3 Medical Technologies
7.5.4 Others
7.6 Pharmacy and Retail
7.6.1 Pharmacies
7.6.2 Drugstores
7.6.3 Retail outlets
7.6.4 Others
7.7 Home Healthcare
7.7.1 Home Nursing
7.7.2 Medical equipment
7.7.3 In-home monitoring
7.7.4 Others
7.8 Diagnostics
7.8.1 Medical imaging
7.8.2 Blood tests
7.8.3 Genetic testing
7.8.4 Others
7.9 Health and Wellness
7.9.1 Fitness
7.9.2 Nutrition
7.9.3 Wellness products and services
8. Regional Analysis
8.1 Introduction
8.2 North America
8.2.1 Trend Analysis
8.2.2 North America Healthcare Market, By Country
8.2.3 North America Healthcare Market Segmentation, By Type
8.2.4 USA
8.2.4.1 USA Healthcare Market Segmentation, By Type
8.2.5 Canada
8.2.5.1 Canada Healthcare Market Segmentation, By Type
8.2.6 Mexico
8.2.6.1 Mexico Healthcare Market Segmentation, By Type
8.3 Europe
8.3.1 Trend Analysis
8.3.2 Eastern Europe
8.3.2.1 Eastern Europe Healthcare Market, By Country
8.3.2.2 Eastern Europe Healthcare Market Segmentation, By Type
8.3.2.3 Poland
8.3.2.3.1 Poland Healthcare Market Segmentation, By Type
8.3.2.4 Romania
8.3.2.4.1 Romania Healthcare Market Segmentation, By Type
8.3.2.5 Hungary
8.3.2.5.1 Hungary Healthcare Market Segmentation, By Type
8.3.2.6 Turkey
8.3.2.6.1 Turkey Healthcare Market Segmentation, By Type
8.3.2.7 Rest of Eastern Europe
8.3.2.7.1 Rest of Eastern Europe Healthcare Market Segmentation, By Type
8.3.3 Western Europe
8.3.3.1 Western Europe Healthcare Market, By Country
8.3.3.2 Western Europe Healthcare Market Segmentation, By Type
8.3.3.3 Germany
8.3.3.3.1 Germany Healthcare Market Segmentation, By Type
8.3.3.4 France
8.3.3.4.1 France Healthcare Market Segmentation, By Type
8.3.3.5 UK
8.3.3.5.1 UK Healthcare Market Segmentation, By Type
8.3.3.6 Italy
8.3.3.6.1 Italy Healthcare Market Segmentation, By Type
8.3.3.7 Spain
8.3.3.7.1 Spain Healthcare Market Segmentation, By Type
8.3.3.8 Netherlands
8.3.3.8.1 Netherlands Healthcare Market Segmentation, By Type
8.3.3.9 Switzerland
8.3.3.9.1 Switzerland Healthcare Market Segmentation, By Type
8.3.3.10 Austria
8.3.3.10.1 Austria Healthcare Market Segmentation, By Type
8.3.3.11 Rest of Western Europe
8.3.3.11.1 Rest of Western Europe Healthcare Market Segmentation, By Type
8.4 Asia-Pacific
8.4.1 Trend Analysis
8.4.2 Asia-Pacific Healthcare Market, By Country
8.4.3 Asia-Pacific Healthcare Market Segmentation, By Type
8.4.4 China
8.4.4.1 China Healthcare Market Segmentation, By Type
8.4.5 India
8.4.5.1 India Healthcare Market Segmentation, By Type
8.4.6 Japan
8.4.6.1 Japan Healthcare Market Segmentation, By Type
8.4.7 South Korea
8.4.7.1 South Korea Healthcare Market Segmentation, By Type
8.4.8 Vietnam
8.4.8.1 Vietnam Healthcare Market Segmentation, By Type
8.4.9 Singapore
8.4.9.1 Singapore Healthcare Market Segmentation, By Type
8.4.10 Australia
8.4.10.1 Australia Healthcare Market Segmentation, By Type
8.4.11 Rest of Asia-Pacific
8.4.11.1 Rest of Asia-Pacific Healthcare Market Segmentation, By Type
8.5 Middle East & Africa
8.5.1 Trend Analysis
8.5.2 Middle East
8.5.2.1 Middle East Healthcare Market, By Country
8.5.2.2 Middle East Healthcare Market Segmentation, By Type
8.5.2.3 UAE
8.5.2.3.1 UAE Healthcare Market Segmentation, By Type
8.5.2.4 Egypt
8.5.2.4.1 Egypt Healthcare Market Segmentation, By Type
8.5.2.5 Saudi Arabia
8.5.2.5.1 Saudi Arabia Healthcare Market Segmentation, By Type
8.5.2.6 Qatar
8.5.2.6.1 Qatar Healthcare Market Segmentation, By Type
8.5.2.7 Rest of Middle East
8.5.2.7.1 Rest of Middle East Healthcare Market Segmentation, By Type
8.5.3 Africa
8.5.3.1 Africa Healthcare Market, By Country
8.5.3.2 Africa Healthcare Market Segmentation, By Type
8.5.3.3 Nigeria
8.5.3.3.1 Nigeria Healthcare Market Segmentation, By Type
8.5.3.4 South Africa
8.5.3.4.1 South Africa Healthcare Market Segmentation, By Type
8.5.3.5 Rest of Africa
8.5.3.5.1 Rest of Africa Healthcare Market Segmentation, By Type
8.6 Latin America
8.6.1 Trend Analysis
8.6.2 Latin America Healthcare Market, By Country
8.6.3 Latin America Healthcare Market Segmentation, By Type
8.6.4 Brazil
8.6.4.1 Brazil Healthcare Market Segmentation, By Type
8.6.5 Argentina
8.6.5.1 Argentina Healthcare Market Segmentation, By Type
8.6.6 Colombia
8.6.6.1 Colombia Healthcare Market Segmentation, By Type
8.6.7 Rest of Latin America
8.6.7.1 Rest of Latin America Healthcare Market Segmentation, By Type
9. Company Profiles
9.1 Pfizer
9.1.1 Company Overview
9.1.2 Financial
9.1.3 Products/ Services Offered
9.1.4 The SNS View
9.2 Novartis
9.2.1 Company Overview
9.2.2 Financial
9.2.3 Products/ Services Offered
9.2.4 The SNS View
9.3 Roche
9.3.1 Company Overview
9.3.2 Financial
9.3.3 Products/ Services Offered
9.3.4 The SNS View
9.4 Merck & Co.
9.4.1 Company Overview
9.4.2 Financial
9.4.3 Products/ Services Offered
9.4.4 The SNS View
9.5 GSK
9.5.1 Company Overview
9.5.2 Financial
9.5.3 Products/ Services Offered
9.5.4 The SNS View
9.6 Sanofi
9.6.1 Company Overview
9.6.2 Financial
9.6.3 Products/ Services Offered
9.6.4 The SNS View
13.7 Johnson & Johnson
9.7.1 Company Overview
9.7.2 Financial
9.7.3 Products/ Services Offered
9.7.4 The SNS View
9.8 AstraZeneca
9.8.1 Company Overview
9.8.2 Financial
9.8.3 Products/ Services Offered
9.8.4 The SNS View
9.9 AbbVie
9.9.1 Company Overview
9.9.2 Financial
9.9.3 Products/ Services Offered
9.9.4 The SNS View
9.10 Medtronic plc
9.10.1 Company Overview
9.10.2 Financial
9.10.3 Products/ Services Offered
9.10.4 The SNS View
10. Competitive Landscape
10.1 Competitive Benchmarking
10.2 Market Share Analysis
10.3 Recent Developments
10.3.1 Industry News
10.3.2 Company News
10.3.3 Mergers & Acquisitions
11. Use Case and Best Practices
12. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments
Type
Pharmaceuticals
Production and distribution of prescription
Over-the-counter drug
Biologics
Others
Healthcare Services
Hospitals
Clinics
Nursing homes
Others
Medical Devices
MRI machines
Pacemakers
Surgical instruments
Diagnostic equipment
Others
Biotechnology
Development of new drugs
Therapies
Medical Technologies
Others
Pharmacy and Retail
Pharmacies
Drugstores
Retail outlets
Others
Home Healthcare
Home nursing
Medical equipment
In-home monitoring
Others
Diagnostics
Medical imaging
Blood tests
Genetic testing
Others
Health and Wellness
Fitness
Nutrition
Wellness products and services
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of the Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Product Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Product Matrix which gives a detailed comparison of the product portfolio of each company
Geographic Analysis
Additional countries in any of the regions
Company Information
Detailed analysis and profiling of additional market players (Up to five)
The Companion Diagnostics Market Size, valued at USD 7.66 billion in 2023, is expected to reach USD 21.15 billion by 2032, with a CAGR of 11.9%.
The Antisense and RNAi therapeutics Market size is projected to reach USD 18.48 billion by 2032, growing at a CAGR of 18.05% over 2024-2032. The market was valued at USD 4.15 billion in 2023.
The 3D Cell Culture Market size was estimated at USD 1.37 billion in 2023 and is expected to reach USD 5.14 billion by 2031 with a growing CAGR of 14.59% during the forecast period of 2024-2031.
The Diet Pills Market size is expected to reach USD 3.77 Bn by 2032 and was valued at USD 1.61 Bn in 2023, the CAGR is expected to be 9.9% over the forecast period of 2024-2032.
The ECG Patch & Holter Monitor Market size was valued at USD 1.60 Billion in 2023 and is expected to reach USD 7.78 Billion by 2032 and grow at a CAGR of 19.23% over the forecast period 2024-2032.
The Artificial Intelligence in Ultrasound Imaging Market size was valued at $889.1 Mn in 2023 and is expected to reach $2047.7 Mn by 2032 and grow at a CAGR of 8.7% over the global forecast period of 2024-2032.
Hi! Click one of our member below to chat on Phone